Citation Impact
Citing Papers
Cytogenetic Profile Predicts Prognosis of Patients With Clear Cell Renal Cell Carcinoma
2009
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
2010 Standout
Global Cancer Incidence and Mortality Rates and Trends—An Update
2015 Standout
Genetic and Functional Studies Implicate HIF1 α as a 14q Kidney Cancer Suppressor Gene
2011 StandoutNobel
Chromosome Abnormalities and Genetic Counseling
2011
Recent developments in esophageal adenocarcinoma
2013
Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study
2016
Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer
2016
De novo design of modular and tunable protein biosensors
2021 StandoutNatureNobel
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013
Breast cancer
2019 Standout
The extracellular domain of Her2 in serum as a biomarker of breast cancer
2018
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
2014
Gastric cancer
2016 Standout
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology
2017
Triple-negative breast cancer molecular subtyping and treatment progress
2020 Standout
WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial
2013
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
2018 Standout
Mosaicism for trisomy 21: A review
2014
Understanding adolescence as a period of social–affective engagement and goal flexibility
2012 Standout
Cognition and the Sex Chromosomes: Studies in Turner Syndrome
2006
Lymphoma-Specific Genetic Aberrations in Microvascular Endothelial Cells in B-Cell Lymphomas
2004
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
New Insights into the Biology of Renal Cell Carcinoma
2011 StandoutNobel
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
Pancreatic cancer
2016 Standout
Tumour heterogeneity in the clinic
2013 Nature
Care of Girls and Women with Turner Syndrome: A Guideline of the Turner Syndrome Study Group
2006
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study
2014
ErbB targeting inhibitors repress cell migration of esophageal squamous cell carcinoma and adenocarcinoma cells by distinct signaling pathways
2014
Timing of Pubertal Maturation in Girls: An Integrated Life History Approach.
2004 Standout
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
2017 Standout
The VHL/HIF axis in clear cell renal carcinoma
2012 StandoutNobel
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
2011 Standout
Familial influences on ovulatory function in common marmosets (Callithrix jacchus)
1997
Gastric cancer
2020 Standout
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Pathology and Molecular Genetics of Pancreatic Neoplasms
2012
Absent or hypoplastic thymus on ultrasound: a marker for deletion 22q11.2 in fetal cardiac defects
2002
Health Supervision for Children With Down Syndrome
2011 Standout
22q11.2 deletion syndrome
2015 Standout
Maftools: efficient and comprehensive analysis of somatic variants in cancer
2018 Standout
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
2013
Angiogenesis as a therapeutic target
2005 StandoutNature
Prenatal and postnatal diagnosis of 22q11.2 deletion syndrome
2010
Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes
2011
Down Syndrome
2020 Standout
Heterogeneity and cancer.
2014
Comparative Analysis of Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer According to 2007 and 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations
2017
A Population-Based Study of the 22q11.2 Deletion: Phenotype, Incidence, and Contribution to Major Birth Defects in the Population
2003
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
2010 Standout
The MAPK pathway across different malignancies: A new perspective
2014 Standout
Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia
2002
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
2009 Standout
Breast Cancer Treatment
2019 Standout
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
2015 Standout
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
2015 Standout
Small Molecules Drive Big Improvements in Immuno‐Oncology Therapies
2017
Global cancer statistics, 2012
2015 Standout
Impact of the 2013 A merican S ociety of C linical O ncology/C ollege of A merican P athologists guideline recommendations for human epidermal growth factor receptor 2 (HER 2) testing of invasive breast carcinoma: a focus on tumours assessed as ‘equivocal’ for HER 2 gene amplification by fluorescence in‐situ hybridization
2015
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Works of Anne E. Wiktor being referenced
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)
2013
Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas
2012
Mental retardation in Turner syndrome
1991
Fluorescence In Situ Hybridization to Visualize Genetic Abnormalities in Interphase Cells of Acinar Cell Carcinoma, Ductal Adenocarcinoma, and Islet Cell Carcinoma of the Pancreas
2009
Identification of sex chromosome mosaicism: Is analysis of 20 metaphase cells sufficient?
2009
Preclinical validation of fluorescence in situ hybridization assays for clinical practice
2006
Prenatal diagnosis of 22q11.2 deletion when ultrasound examination reveals a heart defect
2001
Ullrich‐Turner syndrome with a small ring X chromosome and presence of mental retardation
1992
A fluorescence in situ hybridization technique for retrospective cytogenetic analysis
1991
Detection of low level sex chromosome mosaicism in Ullrich–Turner syndrome patients
2005
Comparison of Fluorescence In Situ Hybridization (FISH) and Dual-ISH (DISH) in the Determination of HER2 Status in Breast Cancer
2013
Clinical significance of Y chromosome loss in hematologic disease
2000
Adverse Prognostic Impact of Intratumor Heterogeneous HER2 Gene Amplification in Patients With Esophageal Adenocarcinoma
2012
Clinical significance of Y chromosome loss in hematologic disease
2000
Changing pattern for HER2 positivity due to updated ASCO/CAP guidelines for HER2 testing and its impact.
2014
Section E9 of the American College of Medical Genetics technical standards and guidelines: Fluorescence in situ hybridization
2011
Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines
2016